Carbenoxolone does not cross the blood brain barrier: An HPLC study

51Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Carbenoxolone (CBX) is a widely used gap junctional blocker. Considering several reports indicating that transient gap junctional blockade could be a favourable intervention following injuries to central nervous tissue, and some current enthusiasm in studies using systemic injections of CBX, it is imperative to consider the penetration of CBX into central nervous tissue after systemic administrations. So far, only very indirect evidence suggests that CBX penetrates into the central nervous system after systemic administrations. We thus determined the amounts of CBX present in the blood and the cerebrospinal fluid of rats after intraperitoneal administration, using high performance liquid chromatography. Results: CBX was found in the blood o f the animals, up to 90 minutes post-injection. However, the cerebrospinal fluid concentration of CBX was negligible. Conclusion: Thus, we conclude that, most likely, CBX does not penetrate the blood brain barrier and therefore recommend careful consideration in the manner of administration, when a central effect is desired. © 2006 Leshchenko et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Leshchenko, Y., Likhodii, S., Yue, W., Burnham, W. M., & Perez Velazquez, J. L. (2006). Carbenoxolone does not cross the blood brain barrier: An HPLC study. BMC Neuroscience, 7. https://doi.org/10.1186/1471-2202-7-3

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free